Alerts

The TGA advises that the distributor has initiated a recall of Slimming Factor pills (also known as Easy Trim, Que She and Chinese Herbal Diet Pills) as they pose a serious health risk.

OxyELITE Pro capsules (New Formula) pose a serious risk to your health and should not be taken. They contain yohimbine, which is a prohibited import.

New conditions for Di-Gesic and Doloxene (dextropropoxyphene) took effect on 10 October 2013 to ensure safe use, changing how these pain-killers are prescribed and supplied.

This update provides further specific information about the recall of Children's Panadol Baby Drops being undertaken by GlaxoSmithKline (GSK), in conjunction with the TGA, for a misaligned dosing syringe that could lead to accidental overdoses.

Recall due to potential for incorrect blood glucose results.

TGA safety alert on Children’s Panadol Baby Drops warns of potential dosing risks linked to syringe markings, advising careful measurement to avoid overdose in infants.

Recall due to potential for protruding needles.

Prosolution tablets are not approved for sale in Australia. Counterfeit versions of Prosolution tablets contain undeclared tadalafil and sildenafil. Both pose significant health risks if taken without medical advice.

Recall due to replacement due to potential for breakdown.

Vigor Tea poses a serious risk to your health and should not be taken. It contains undeclared sulfoaildenafil and has not been assessed for quality, safety or efficacy.

Recall due to replacement due to potential for miscalibration.

Monitoring communication

TGA warns that mefloquine (Lariam) may cause serious vision problems; seek medical advice if symptoms occur.

Unlocated devices following recall for product correction.

Consumers and health professionals are advised that Janssen-Cilag (Australia), in consultation with the TGA, is deregistering and discontinuing supply of oral ketoconazole (Nizoral) 200 mg tablets, commencing 1 December 2013.

New conditions on Di-Gesic and Doloxene (dextropropoxyphene) will change how these pain-killers are prescribed and supplied to ensure safe use from 10 October 2023.

Changes to radio frequency (RF) spectrums in Australia could affect a small number of biomedical telemetry devices used in hospitals.

Recall for product correction due to potential for aluminium tubing to break.

Recall for product correction due to potential for injury.

TGA safety alert for health professionals on apixaban, dabigatran and rivaroxaban emphasises bleeding risks, careful patient selection, renal function assessment, and adherence to prescribing guidelines.

TGA safety alert providing guidance for consumers on apixaban, dabigatran and rivaroxaban, highlighting the risk of bleeding, safe use, and the importance of not stopping treatment without medical advice.

Recall for product correction due to potential for handle to break.

Recall due to replacement with newer model.

A hazard alert has been issued to cardiologists and surgeons regarding some models of Cognis Cardiac Resynchronisation Therapy Defibrillators (CRT-Ds) and Teligen Implantable Cardioverter Defibrillators (ICDs).

Blue Stinger capsules pose a serious health risk and should not be taken. They contain undeclared sulfoaildenafil and have not been assessed for quality, safety or efficacy.